Pine Michael Craig 4/A
4/A · EyePoint Pharmaceuticals, Inc. · Filed Dec 11, 2023
Insider Transaction Report
Form 4/AAmended
Pine Michael Craig
Chief Corp Dev.&Strat. Officer
Transactions
- Sale
Common Stock
2023-12-04$22.00/sh−45,000$990,000→ 5,343 total - Sale
Common Stock
2023-12-04$20.79/sh−1,000$20,790→ 4,343 total - Exercise/Conversion
Common Stock
2023-12-04$12.62/sh+45,000$567,900→ 50,343 total - Exercise/Conversion
Stock Option (Right to Buy)
2023-12-04−45,000→ 55,000 totalExercise: $12.62Exp: 2032-01-10→ Common Stock (45,000 underlying)
Footnotes (3)
- [F1]Includes 2,159 shares acquired on January 31, 2023 and 2,184 shares acquired on July 31,2023 pursuant to EyePoint's 2019 Employee Stock Purchase Plan.
- [F2]This owned share transaction was inadvertently left off of the original Form 4 filing on December 6, 2023.
- [F3]The option to purchase will vest and become exercisable as follows: 25% at January 10th, 2023 and the remainder ratably, on a monthly basis, over the remaining three years.